Today’s Research Reports on Stocks to Watch: Tonix Pharmaceuticals and Vital Therapies
NEW YORK, NY / ACCESSWIRE / October 4, 2018 / Tonix Pharmaceuticals and Vital Therapies Inc. both saw big gains in Wednesday’s session despite either company releasing any news nor there being any catalyst to set shares off. Tonix was expected to have presented this week at the MicroCap Conference.
RDI Initiates Coverage on:
Tonix Pharmaceuticals Holding Corp.
https://www.rdinvesting.com/report/?ticker=TNXP
Vital Therapies, Inc.
https://www.rdinvesting.com/report/?ticker=VTL
Tonix Pharmaceuticals Holding Corp. shares closed up 17.80% on Wednesday with an additional gain of 5.04% in after-hours trading. The company's CEO Seth Lederman M.D. was expected to present and host investor meetings at the MicroCap Conference on October 1-2, 2018, in New York City. The biopharma company is developing Tonmya, which has been granted Breakthrough Therapy designation, as a bedtime treatment for PTSD. The company is also developing TNX-102 SL as a bedtime treatment for agitation in Alzheimer’s disease under a separate IND to support a Phase 2, potential pivotal, efficacy study and has been granted Fast Track designation by the FDA for this indication. The company's lead biologic candidate, TNX-801, is a potential smallpox-preventing vaccine based on a live synthetic version of horsepox virus, currently in the pre-IND application stage.
Access RDI’s Tonix Pharmaceuticals Holding Corp. Research Report at:
https://www.rdinvesting.com/report/?ticker=TNXP
Vital Therapies, Inc. shares were up nearly 29% at the close yesterday on skyrocket volume of almost 26 million shares traded. There was no news from the company nor a catalyst to explain the sudden jump in share price and trading volume. The company, which has been developing ELAD®, a cell-based therapy targeting the treatment of liver failure, announced last week additional data from its VTL-308 clinical trial at the 19th International Liver Support Meeting in Rostock-Warnemunde, Germany. It was last month that the company said that it does not believe its ELAD system can win approval in the U.S. or European Union, without additional clinical trials that would cost money and require some time to complete. A trial of the therapy failed to meet its primary or secondary endpoints. "The company will cease any further development of the ELAD System and explore strategic options," Vital said in a statement.
Access RDI’s Vital Therapies, Inc. Research Report at:
https://www.rdinvesting.com/report/?ticker=VTL
Our Actionable Research on Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) and Vital Therapies, Inc. (NASDAQ: VTL) can be downloaded free of charge at Research Driven Investing.
Research Driven Investing
We are committed to providing relevant and actionable information for the self-directed investor. Our research is reputed for being a leader in trusted, in-depth analysis vital for informed strategic trading decisions. The nimble investor can leverage our analysis and collective expertise to execute a disciplined approach to stock selection.
RDInvesting has not been compensated; directly or indirectly; for producing or publishing this document.
Disclaimer: This article is written by an independent contributor of RDInvesting.com and Nadia Noorani, a CFA® charter holder, has provided necessary guidance in preparing the document templates. RDInvesting.com is neither a registered broker-dealer nor a registered investment advisor. For more information please read our full disclaimer at www.rdinvesting.com/disclaimer.
CONTACT
For any questions, inquiries, or comments reach out to us directly at:
Address:
Email:
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: RDInvesting.com
